ArticleCellular & molecular immunology2020
Macrophages reprogrammed by lung cancer microparticles promote tumor development via release of IL-1β.
Article in Cellular & molecular immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 60 citations in OpenAlex.
- Expression of the NLRP12/NF-κB/iNOS axis in lung tissues across stages of non-small cell lung cancer and its mechanism in mediating immune cell regulation.Translational cancer research · 2026Article
- Remodeling the Immune Landscape: How Obesity-Induced SASPs Create a Pro-Tumorigenic Niche.Current obesity reports · 2026Review
- Chessboard Microneedle Array for Inflammation Regulation via Spatiotemporally Controlled Drug Delivery.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Toll-like receptors: versatile players in tumor.Frontiers in immunology · 2026Review
- Review: Progress of the NLRP3 inflammasome in tumours and perspectives for cholangiocarcinoma.Cell communication and signaling : CCS · 2025Review
- Exosomes: a double-edged sword in cancer immunotherapy.MedComm · 2025Review
- The role of macrophages in liver metastasis: mechanisms and therapeutic prospects.Frontiers in immunology · 2025Review
- The success of the tumor immunotherapy: neutrophils from bench to beside.Frontiers in immunology · 2025Review
- Tumor-derived vesicles in immune modulation: focus on signaling pathways.Frontiers in immunology · 2025Review
- Role of toll-like receptors in pulmonary immunity: mechanisms and therapeutic implications.Frontiers in immunology · 2025Review
- Mitochondria in tumor immune surveillance and tumor therapies targeting mitochondria.Cellular oncology (Dordrecht, Netherlands) · 2024Review
- Tumor cell membrane-based vaccines: A potential boost for cancer immunotherapy.Exploration (Beijing, China) · 2024Review
- Microglial CMPK2 promotes neuroinflammation and brain injury after ischemic stroke.Cell reports. Medicine · 2024Article
- Lithium carbonate revitalizes tumor-reactive CD8Nature immunology · 2024Article
- Photodynamic Therapy and Adaptive Immunity Induced by Reactive Oxygen Species: Recent Reports.Cancers · 2024Review
- Crosstalk between lung cancer cells and macrophages contributes to traditional Chinese medicine Feiyanning-induced anti-tumor activities by suppressing M2 macrophage polarization.Acta biochimica et biophysica Sinica · 2023Article
- Microparticle Phosphatidylserine Mediates Coagulation: Involvement in Tumor Progression and Metastasis.Cancers · 2023Review
- Challenges and Opportunities for Extracellular Vesicles in Clinical Oncology Therapy.Bioengineering (Basel, Switzerland) · 2023Review
- Review
- Chemo-drugs in cell microparticles reset antitumor activity of macrophages by activating lysosomal P450 and nuclear hnRNPA2B1.Signal transduction and targeted therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite their mutual antagonism, inflammation and immunosuppression coexist in tumor microenvironments due to tumor and immune cell interactions, but the underlying mechanism remains unclear. Previously, we showed that tumor cell-derived microparticles induce an M2 phenotype characterized by immunosuppression in tumor-infiltrating macrophages. Here, we further showed that lung cancer microparticles (L-MPs) induce macrophages to release a key proinflammatory cytokine, IL-1β, thus promoting lung cancer development. The underlying mechanism involves the activation of TLR3 and the NLRP3 inflammasome by L-MPs. More importantly, tyrosine kinase inhibitor treatment-induced L-MPs also induce human macrophages to release IL-1β, leading to a tumor-promoting effect in a humanized mouse model. These findings demonstrated that in addition to their anti-inflammatory effect, L-MPs induce a proinflammatory phenotype in tumor-infiltrating macrophages, promoting the development of inflammatory and immunosuppressive tumor microenvironments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.